JERSEY CITY, N.J., June 21, 2024 /PRNewswire/ -- InsightAce Analytic
Pvt. Ltd. announces the release of a market assessment report on
the "Global Weight Loss Drugs Market- (By Drug Type
(Prescription and Over-the-counter), By Product (Wegovy, Ozempic,
Saxenda, Zepbound, Mounjaro and Others)), By Distribution Channel,
By Region, Trends, Industry Competition Analysis, Revenue and
Forecast To 2031."
According to the latest research by InsightAce Analytic, the
Global Weight Loss Drugs Market is valued at US$ 26.3 Bn in 2023, and it is expected to
reach US$ 108.9 Bn by 2031,
with a CAGR of 19.7% during the forecast period of
2024-2031.
Download Free Sample Report
Pages: https://www.insightaceanalytic.com/request-sample/2526
Weight loss drugs work through various mechanisms in the body to
promote weight loss, such as reducing appetite, increasing feelings
of fullness, decreasing absorption of nutrients, or increasing
calorie expenditure.
The weight loss drugs market is propelled by the escalating
global obesity crisis and increasing societal emphasis on health
and wellness. As obesity rates surge worldwide, there is a
heightened demand for effective weight management solutions.
Concurrently, a cultural shift towards prioritizing health and
fitness encourages individuals to seek tools to achieve and
maintain a healthy weight. These intertwined factors create a
robust market for weight loss drugs, motivating pharmaceutical
companies to innovate and develop new treatments to address the
pressing need for effective weight management solutions.
One significant opportunity in the global weight loss and
anti-obesity drugs market lies in developing personalized medicine
approaches. As scientific understanding of genetics, metabolism,
and individual responses to medications advances, there is a
growing potential to tailor weight loss treatments to each person's
unique biology. A major restraint of the market revolves around
safety concerns, potential side effects, and regulatory hurdles,
which are significant factors that pharmaceutical companies must
navigate when developing and marketing weight loss medications.
List of Prominent Players in the Weight Loss Drugs
Market:
- Novo Nordisk A/S
- Eli Lilly & Co.
- Amgen Inc.
- Pfizer Inc.
- Viking Therapeutics Inc.
- Structure Therapeutics Inc.
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Sandoz International GmbH
Order Full 180 Pages Report @
https://www.insightaceanalytic.com/buy-report/2526
Market Dynamics:
Drivers:
Obesity stands out as the primary driver in the weight loss drug
market due to its alarming global prevalence and associated health
risks. With the rising incidence of obesity-related conditions like
diabetes, cardiovascular diseases, and certain cancers, there's a
growing demand for effective weight management solutions.
According to World Health Organization estimate, the number of
adults living with obesity will rise from 1 billion in 2022 to 1.53
billion in 2035. In recent, increase in new treatment options for
weight loss is likely to drive the market growth. For instance,
currently GLP-1 receptor agonist product like Wegovy and Saxenda is
very popular due to high efficacy in weight loss. It also helps to
improved glycemic control, reduction in HbA1c levels, etc.
Challenges:
The weight loss drugs market faces several challenges. One major
hurdle is the limited long-term efficacy of many weight loss drugs.
Weight loss can be not easy to maintain over time, and many drugs
on the market offer only short-term benefits. Additionally, safety
concerns and potential side effects associated with weight loss
drugs pose significant challenges, leading to regulatory scrutiny
and sometimes even withdrawal from the market. Another challenge is
the high cost of some weight loss drugs, making them inaccessible
to many patients.
Regional Trends:
The North American weight loss drugs market is seen to register
a major market share in terms of revenue and is estimated to grow
at a high CAGR in the near future. Rising concerns about obesity
and chronic diseases are prompting individuals to seek effective
solutions for weight management. With a substantial portion of the
population categorized as overweight or obese, there is a pressing
need for interventions that can help address these health issues,
resulting in driving the market.
Asia-Pacific is expected to
grow significantly during the forecasted period. Rising obesity
rates, changing lifestyles, increased disposable income, and
growing awareness about health and wellness have all contributed to
the growth of this market. Additionally, cultural shifts towards
valuing a slim physique and the desire for quick-fix solutions have
further propelled the demand for weight loss drugs.
Curious about this latest version of the report? @
https://www.insightaceanalytic.com/enquiry-before-buying/2526
Recent Developments:
- In March 2024, Novo Nordisk
announced that its new drug, amycretin, for fighting obesity is
performing better than its previous drug, Wegovy, in the
trials.
- In November 2023, the U.S. Food
and Drug Administration (FDA) approved Eli Lilly and Company's
Zepbound (tirzepatide) injection, the first and only obesity
treatment that activates both GIP (glucose-dependent insulinotropic
polypeptide) and GLP-1 (glucagon-like peptide-1) hormone
receptors.
- In December 2023, Roche Holding
AG, a Switzerland-based healthcare
company, successfully acquired Carmot Therapeutics Inc. for
$2.7 billion.
Segmentation of Weight Loss Drugs Market
Weight Loss Drugs Market- By Drug Type
- Prescription
- Over-the-counter
Weight Loss Drugs Market- By Drug Class
- Appetite Suppression
- Fat Blocking
- GLP-1 Receptor Agonist
- Others
Weight Loss Drugs Market- By Product
- Wegovy
- Ozempic
- Saxenda
- Zepbound
- Mounjaro
- Others
Weight Loss Drugs Market- By Distribution
Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Weight Loss Drugs Market- By Region
North America-
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and
Africa
For More Customization @
https://www.insightaceanalytic.com/customisation/2526
About Us:
InsightAce Analytic is a market research and consulting firm
that enables clients to make strategic decisions. Our qualitative
and quantitative market intelligence solutions inform the need for
market and competitive intelligence to expand businesses. We help
clients gain competitive advantage by identifying untapped markets,
exploring new and competing technologies, segmenting potential
markets and repositioning products. Our expertise is in providing
syndicated and custom market intelligence reports with an in-depth
analysis with key market insights in a timely and cost-effective
manner.
Contact Us:
InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn:
https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Logo:
https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/weight-loss-drugs-a-game-changer-in-the-fight-against-obesity---new-insightace-analytic-report-investigates-302178821.html